We are live on ! Find out more
TNGX icon

Tango Therapeutics
TNGX

92 hedge funds and large institutions have $276M invested in Tango Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

12% more funds holding

Funds holding: 82 → 92 (+10)

1.22% more ownership

Funds ownership: 77.96% → 79.18% (+1.2%)

9% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 23

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

45% less capital invested

Capital invested by funds: $498M → $276M (-$223M)

Holders
92
Holders Change
+10
Holders Change %
+12.2%
% of All Funds
1.47%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
18
Increased
25
Reduced
23
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$5.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.47M
3
TCM
Tang Capital Management
California
+$1.16M
4
Millennium Management
Millennium Management
New York
+$981K
5
Squarepoint
Squarepoint
New York
+$538K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$2.1M
2
FCM
Farallon Capital Management
California
-$1.96M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.12M
4
Invesco
Invesco
Georgia
-$1.1M
5
OMC
Oasis Management Company
Cayman Islands
-$848K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP IV
Massachusetts
$76.5M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$37.6M +$2.47M +425,250 +5%
BC
3
Boxer Capital
California
$28.1M – – –
SCA
4
Southpoint Capital Advisors
New York
$17.8M – – –
EC
5
EcoR1 Capital
California
$16.6M – – –
CAM
6
Cormorant Asset Management
Massachusetts
$16.3M – – –
BlackRock
7
BlackRock
New York
$14M -$71.1K -12,259 -0.3%
Vanguard Group
8
Vanguard Group
Pennsylvania
$10.9M +$204K +35,110 +1%
BCLSI
9
Bain Capital Life Sciences Investors
Massachusetts
$7.59M – – –
ACA
10
Avoro Capital Advisors
New York
$6.48M – – –
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$4.71M -$48.3K -8,319 -0.7%
CC
12
Casdin Capital
New York
$3.95M +$5.8M +1,000,000 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$3.5M +$200K +34,503 +4%
State Street
14
State Street
Massachusetts
$3.25M -$130K -22,340 -3%
BBA
15
Baker Bros. Advisors
New York
$2.96M – – –
HMC
16
Harvard Management Company
Massachusetts
$2.8M – – –
Bessemer Group
17
Bessemer Group
New Jersey
$2.8M – – –
SB
18
Samsara BioCapital
California
$2.49M – – –
Ensign Peak Advisors
19
Ensign Peak Advisors
Utah
$1.96M – – –
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$1.6M +$343K +59,094 +17%
Northern Trust
21
Northern Trust
Illinois
$1.57M -$59.4K -10,239 -3%
WP
22
Woodline Partners
California
$1.43M -$23.5K -4,042 -1%
TCM
23
Tang Capital Management
California
$790K +$1.16M +200,000 New
Millennium Management
24
Millennium Management
New York
$783K +$981K +168,948 +578%
Citadel Advisors
25
Citadel Advisors
Florida
$684K -$1.12M -192,323 -53%
1
2 3 4

TNGX Hedge Fund Activity: Q1 2023 in Review

92 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2023, worth a combined $276M — down 45% from $498M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TNGX positions and 8 closed out — a net gain of 10 holders — while 25 added to existing stakes and 23 trimmed.

The largest buyer was Casdin Capital, opening a new position worth an estimated $5.8M. The largest seller was Walleye Capital, exiting entirely with an estimated $2.1M sold.

  • 92 institutional investors held Tango Therapeutics (TNGX) as of Q1 2023, up from 82 in Q4 2022.
  • Funds reported $276M of Tango Therapeutics stock for Q1 2023, down 45% quarter-over-quarter.
  • 18 funds opened new Tango Therapeutics positions in Q1 2023 and 8 closed out, a net change of +10 holders.
  • The largest Tango Therapeutics buyer in Q1 2023 was Casdin Capital, an estimated $5.8M added.
  • The largest Tango Therapeutics seller in Q1 2023 was Walleye Capital, an estimated $2.1M sold.

Based on aggregated 13F filings for Q1 2023.